151 related articles for article (PubMed ID: 38831704)
1. Real-world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients.
Cranwell W; Meah N; Wall D; Bevin B; Laita B; Sinclair RD
Australas J Dermatol; 2024 Jun; ():. PubMed ID: 38831704
[TBL] [Abstract][Full Text] [Related]
2. A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis.
Sharath S; Sardana K; Khurana A
Indian Dermatol Online J; 2024; 15(1):49-54. PubMed ID: 38282998
[TBL] [Abstract][Full Text] [Related]
3. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
4. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: A retrospective study.
Jerjen R; Meah N; Trindade de Carvalho L; Wall D; Eisman S; Sinclair R
Pediatr Dermatol; 2021 Jan; 38(1):103-108. PubMed ID: 33099833
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
7. Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: A prospective, open-label, single-center study in Asian Arab population.
Husein-ElAhmed H; Abdulla N; Al-Obaidli A; Ali-Alam M; Steinhoff M
Dermatol Ther; 2022 Dec; 35(12):e15871. PubMed ID: 36177791
[TBL] [Abstract][Full Text] [Related]
8. Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study.
Zhang W; Li X; Chen B; Zhang J; Torres-Culala KMT; Zhou C
Front Med (Lausanne); 2022; 9():891434. PubMed ID: 35801202
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Tofacitinib in Pre-adolescent Alopecia Areata: A Retrospective Case Series and Literature Review.
Huang J; Li T; Tan Z; Tang Y; Li J; Liu F; Shi W
Acta Derm Venereol; 2023 Sep; 103():adv13418. PubMed ID: 37731213
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients.
Shivanna CB; Shenoy C; Priya RA
Int J Trichology; 2018; 10(3):103-107. PubMed ID: 30034188
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
Benton S; Farah R; Freese R; Hordinsky M
Dermatol Ther; 2022 Apr; 35(4):e15310. PubMed ID: 34997820
[TBL] [Abstract][Full Text] [Related]
12. Oral tofacitinib for the treatment of alopecia areata in pediatric patients.
Kibbie J; Kines K; Norris D; Dunnick CA
Pediatr Dermatol; 2022 Jan; 39(1):31-34. PubMed ID: 34779041
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study.
Huang J; Qian P; Tang Y; Li J; Liu F; Shi W
Acta Derm Venereol; 2023 Dec; 103():adv12425. PubMed ID: 38112208
[TBL] [Abstract][Full Text] [Related]
14. Treatments for alopecia areata: a network meta-analysis.
Mateos-Haro M; Novoa-Candia M; Sánchez Vanegas G; Correa-Pérez A; Gaetano Gil A; Fernández-García S; Ortega-Quijano D; Urueña Rodriguez MG; Saceda-Corralo D; Bennouna-Dalero T; Giraldo L; Tomlinson J; Vaño-Galván S; Zamora J
Cochrane Database Syst Rev; 2023 Oct; 10(10):CD013719. PubMed ID: 37870096
[TBL] [Abstract][Full Text] [Related]
15. Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population.
AlMarzoug A; AlOrainy M; AlTawil L; AlHayaza G; AlAnazi R; AlIssa A; AlSheikh A; AlKhalifah A; AlHarithy R
Int J Dermatol; 2022 Jul; 61(7):886-894. PubMed ID: 34716573
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Yu L; Yu H; Zhang S; Hao Y; Zhang S
Front Immunol; 2022; 13():904156. PubMed ID: 35795663
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of tofacitinib in 97 alopecia areata patients.
Nasimi M; Abedini R; Ghandi N; Teymourpour A; Babaie H
J Cosmet Dermatol; 2024 May; ():. PubMed ID: 38736269
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
Craiglow BG; Liu LY; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
[TBL] [Abstract][Full Text] [Related]
20. Experience with oral tofacitinib in severe alopecia areata with different clinical responses.
Dincer Rota D; Emeksiz MAC; Erdogan FG; Yildirim D
J Cosmet Dermatol; 2021 Sep; 20(9):3026-3033. PubMed ID: 33533091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
